Barcelona, [July 2nd, 2025] — The Board of Directors of Peptomyc S.L., a pioneering biotech company developing innovative cancer therapies targeting the MYC oncoprotein, is pleased to announce a strategic leadership transition aimed at accelerating the company’s business development and clinical expansion efforts.
Effective July 2nd, 2025, Jesus Martin Garcia will assume the role of Chief Executive Officer (CEO). Jesus brings a strong track record in business development, strategic partnerships, and company scaling across the biotech and pharmaceutical sectors. His leadership is expected to reinforce Peptomyc’s corporate growth and partnering strategy as the company advances its clinical pipeline and explores new therapeutic opportunities, including its promising radioligand program.
Laura Soucek, co-founder of Peptomyc and current CEO, will transition to the role of Chief Scientific Officer (CSO), where she will continue to drive the company’s R&D strategy and scientific vision. Laura’s pioneering research has been the cornerstone of Peptomyc’s therapeutic platform, and her continued leadership in scientific development ensures strong continuity and innovation at the company’s core.
In parallel, Marie-Eve Beaulieu, co-founder and current CSO, will transition to Chief Development Officer (CDO). She will continue to lead pharmaceutical development operations and pipeline strategy, applying her scientific and market insight to shape innovation priorities and advance high-value programs such as the radioligand platform.
“This evolution in our leadership structure reflects our confidence in the strength of Peptomyc’s science and our commitment to building a sustainable, growth-oriented future”, said Laura Soucek. “I am thrilled to welcome Jesus to the team as our new CEO. His experience in business development and corporate leadership will be invaluable as we move into our next stage of growth and strategic partnerships”, added Giacomo Di Nepi, Chairman of the Board.
Jesus Martin Garcia commented, “I am honored to join Peptomyc at such a pivotal time in its journey. The company’s groundbreaking approach to targeting MYC and its expanding clinical pipeline position it for meaningful impact in oncology. I look forward to working closely with the Board, which I thank for the opportunity, and the Management team, to realize the full potential of the Peptomyc platform and to deliver value for patients, partners, and shareholders.”
This transition strengthens Peptomyc’s leadership to deliver key clinical milestones across its MYC-directed programs, while actively preparing for its next development stages.
About Peptomyc
Peptomyc S.L. is a Barcelona-based biotechnology company focused on developing a new class of peptide therapeutics that directly inhibit MYC, a key driver in many types of cancer. Founded by leading oncology scientists, Peptomyc is advancing a novel pipeline with the potential to transform cancer treatment.